134 related articles for article (PubMed ID: 1906658)
1. In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a.
de Riese W; Allhoff E; Stief CG; Lenis G; Schlick R; Liedke S; Anton P; Jonas U
Urol Res; 1991; 19(2):87-90. PubMed ID: 1906658
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.
Sella A; Logothetis CJ; Fitz K; Dexeus FH; Amato R; Kilbourn R; Wallace S
J Urol; 1992 Mar; 147(3):573-7. PubMed ID: 1538431
[TBL] [Abstract][Full Text] [Related]
3. Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay.
Homma Y; Aso Y
Eur Urol; 1994; 25(2):164-70. PubMed ID: 8137859
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
[TBL] [Abstract][Full Text] [Related]
5. Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma.
Küpeli S; Beksac M; Küpeli B; Baltaci S; Süzer O
Int Urol Nephrol; 1997; 29(4):421-6. PubMed ID: 9405998
[TBL] [Abstract][Full Text] [Related]
6. Combined interferon and vinblastine treatment of advanced melanoma and renal cell cancer.
Kellokumpu-Lehtinen P; Nordman E
Cancer Detect Prev; 1988; 12(1-6):523-9. PubMed ID: 3180144
[TBL] [Abstract][Full Text] [Related]
7. Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy--a pilot study.
Kröger MJ; Menzel T; Gschwend JE; Bergmann L
Anticancer Res; 1999; 19(2C):1553-5. PubMed ID: 10365144
[TBL] [Abstract][Full Text] [Related]
8. Combination of recombinant interferon alpha-2A and vinblastine in advanced renal cell cancer.
Schuster D; Schneider G; Ade N; Heim ME
Onkologie; 1990 Oct; 13(5):359-62. PubMed ID: 2082231
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
10. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma.
Fosså SD; de Garis ST; Heier MS; Flokkmann A; Lien HH; Salveson A; Moe B
Cancer; 1986 Apr; 57(8 Suppl):1700-4. PubMed ID: 3948141
[TBL] [Abstract][Full Text] [Related]
12. In vitro drug sensitivity testing of human testicular germ cell tumours with cytostatic drugs and interferon alpha-2b.
Küpeli B; Baltaci S; Beksac M; Süzer O; Küpeli S; Göğüs O
Int Urol Nephrol; 1997; 29(1):79-84. PubMed ID: 9203042
[TBL] [Abstract][Full Text] [Related]
13. Immune reactive proteins in renal cell carcinoma patients treated by IFN alpha alone or in combination with vinblastine.
Juranić Z; Stanojević-Bakić N; Maletić V; Borkovacki R
Neoplasma; 1994; 41(4):229-32. PubMed ID: 7935998
[TBL] [Abstract][Full Text] [Related]
14. Our experience with interferon alpha: renal cell carcinoma.
Merimsky O; Chaitchik S
Mol Biother; 1992 Sep; 4(3):130-4. PubMed ID: 1445666
[TBL] [Abstract][Full Text] [Related]
15. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
16. Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma.
Rizzo M; Bartoletti R; Selli C; Sicignano A; Criscuolo D
Eur Urol; 1989; 16(4):271-7. PubMed ID: 2670581
[TBL] [Abstract][Full Text] [Related]
17. Prognostic indicators for response to therapy and survival in patients with metastatic renal cell cancer treated with interferon alpha-2 beta and vinblastine.
Papadopoulos I; Rudolph P; Weichert-Jacobsen K; Thiemann O; Papadopoulou D
Urology; 1996 Sep; 48(3):373-8. PubMed ID: 8804488
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.
Schornagel JH; Verweij J; ten Bokkel Huinink WW; Klijn JG; de Mulder PH; Debruyne FM; van Deijk WA; Roozendaal K; Kok TC; Veenhof KH
J Urol; 1989 Aug; 142(2 Pt 1):253-6. PubMed ID: 2746739
[TBL] [Abstract][Full Text] [Related]
19. [Interferon-alpha therapy in hypernephroma].
Sagaster KP
Wien Med Wochenschr; 1993; 143(16-17):443-7. PubMed ID: 8273370
[TBL] [Abstract][Full Text] [Related]
20. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
Jeon SH; Chang SG; Kim JI
Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
